X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small molecule.
Lead Product(s): Dinutuximab
Therapeutic Area: Oncology Product Name: Qarziba
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Recordati
Deal Size: $847.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 03, 2021
Details:
This pivotal study will evaluate the efficacy and safety of standard of care (SOC) with or without intravenous siltuximab in selected hospitalised patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection.
Lead Product(s): Siltuximab
Therapeutic Area: Infections and Infectious Diseases Product Name: Sylvant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.
Lead Product(s): Dinutuximab
Therapeutic Area: Oncology Product Name: Qarziba
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The Phase 2 portion of the study was designed to assess the safety, tolerability, and anti-tumor activity of the full dose and schedule of PO tivozanib, in combination with IV nivolumab.
Lead Product(s): Tivozanib,Nivolumab
Therapeutic Area: Oncology Product Name: Fotivda
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Aveo Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling.
Lead Product(s): Siltuximab
Therapeutic Area: Infections and Infectious Diseases Product Name: Sylvant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2020
Details:
A third of patients with COVID-19 taking EUSA Pharma's interleukin (IL)-6 targeted monoclonal antibody siltuximab have experienced a clinical improvement, reveals a case-control trial in Italy.
Lead Product(s): Siltuximab
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
The step was followed by the release of initial data from China suggesting a role of IL-6 in the development of Acute Respiratory Distress Syndrome as a result of COVID-19.
Lead Product(s): Siltuximab
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
